Patent ID: 8409813
Filing Date: 2013-04-02
Classification: A61P,C12N,C12Q,G01N

Abstract:
1. A method for treating a subject having a melanoma comprising: a) determining whether melanoma cells in said subject express a TLR3 receptor comprising SEQ ID NO: 2, the expression of a TLR3 receptor comprising SEQ ID NO: 2 being indicative of a subject responding to a TLR3 agonist selected from poly I: poly C (poly IC), poly A: poly U (polyAU), and b) administering to said subject whose melanoma cells are determined to express a TLR3 receptor comprising SEQ ID NO: 2 a pharmaceutical composition comprising an effective amount of a TLR3 agonist selected from poly I: poly C (poly IC) or poly A: poly U (poly AU), and a pharmaceutically acceptable carrier.